Vera Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Vera Therapeutics, Inc. (VERA) reported Proceeds from Sale and Maturity of Marketable Securities of $218.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-10
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $131.03M, a 3.94% increase year-over-year.
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $87.92M, a 17.25% decline year-over-year.
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $126.06M, a 115.49% increase year-over-year.
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-03-31 was $106.25M, a 235.36% increase year-over-year.
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $506.16M, a 84.09% increase from fiscal 2024.
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $274.96M, a 56.21% increase from fiscal 2023.
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $176.02M, a 125.67% increase from fiscal 2022.
- Vera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $78.00M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $131.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $218.95M 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | $87.92M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $506.16M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $126.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $232.31M 10-Q · filed 2026-08-10 | $305.58M derived: sum of 3 quarters · filed 2026-08-10 | $417.08M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $106.25M 10-Q · filed 2026-05-07 | $179.52M derived: sum of 2 quarters · filed 2026-05-07 | $291.02M derived: sum of 3 quarters · filed 2026-05-07 | $349.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $73.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $184.78M derived: sum of 2 quarters · filed 2026-02-26 | $243.28M derived: sum of 3 quarters · filed 2026-02-26 | $274.96M 10-K · filed 2026-02-26 |
| 2024-09-30 | $111.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $170.00M derived: sum of 2 quarters · filed 2025-08-05 | $201.68M 10-Q · filed 2024-11-07 | $273.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $58.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $90.18M 10-Q · filed 2025-08-05 | $162.00M derived: sum of 3 quarters · filed 2026-02-26 | $206.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $31.68M 10-Q · filed 2025-05-07 | $103.50M derived: sum of 2 quarters · filed 2026-02-26 | $148.40M derived: sum of 3 quarters · filed 2026-02-26 | $170.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $71.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $116.72M derived: sum of 2 quarters · filed 2026-02-26 | $139.12M derived: sum of 3 quarters · filed 2026-02-26 | $176.02M 10-K · filed 2026-02-26 |
| 2023-09-30 | $44.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $67.30M derived: sum of 2 quarters · filed 2024-11-07 | $104.20M 10-Q · filed 2024-11-07 | $128.20M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $22.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $59.30M 10-Q · filed 2024-08-08 | $83.30M derived: sum of 3 quarters · filed 2024-08-08 | $121.30M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $36.90M 10-Q · filed 2024-05-10 | $60.90M derived: sum of 2 quarters · filed 2024-05-10 | $98.90M derived: sum of 3 quarters · filed 2024-05-10 | $114.90M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $62.00M derived: sum of 2 quarters · filed 2024-03-27 | $78.00M derived: sum of 3 quarters · filed 2024-03-27 | $78.00M 10-K · filed 2024-03-27 |
| 2022-09-30 | $38.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $54.00M derived: sum of 2 quarters · filed 2023-11-09 | $54.00M 10-Q · filed 2023-11-09 | $54.00M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $16.00M 10-Q · filed 2023-08-10 | $16.00M derived: sum of 3 quarters · filed 2023-08-10 | $16.00M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |